Could a 3-Step immune therapy save Insulin-Making cells in newly diagnosed type 1 diabetes?
NCT ID NCT07610213
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a three-step immune treatment for people recently diagnosed with Type 1 diabetes (within 6 months). The goal is to preserve the body's remaining insulin production by calming the immune attack and teaching the immune system to tolerate insulin. Sixty adults aged 18-45 will receive either the MATIN-2 protocol or standard care, with safety and insulin production monitored for two years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kara Harp Okulu (Turkish Military Academy)
Ankara, Ankara, 06000, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a smart pen take the guesswork out of insulin dosing?
- AI takes the wheel: could a smart algorithm optimize insulin pumps from home?
- Can a common diabetes pill make insulin therapy safer and more effective for type 1 diabetes?
- Video game meets glucose monitor: a new way to teach diabetes skills to children
- Real-World test of automated insulin system aims to improve blood sugar control for type 1 diabetes
- Can a wearable sensor help young people with type 1 diabetes tame blood sugar swings?